Contents
On this page
- The two layers of GPP reporting and the informal handling of the second
- Selection of the reporting guideline and its value
- Most frequently omitted reporting items
- The seven GPP declarations
- The abstract as a separate reporting object
- Alternative reporting of identical results
- Outputs other than journal articles
- Scope and limits of the reporting evidence
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Publication · GPP reporting standards
Reporting and Declaration Requirements Under GPP: A Working Checklist
GPP reporting operates in two layers. The first is the reporting guideline for the study design, which GPP expects authors to follow but does not itself contain. The second is a set of declarations (authorship, contributions, sponsor role, data access, prior disclosure and data availability) that no reporting guideline covers. Most publications address the first layer adequately and the second from memory.
Checklists are useful in proportion to their specificity, and this article is therefore structured as one. The underlying claim is straightforward: a GPP-compliant publication must satisfy two different checklists, and authors tend to be aware of only one. The reporting guideline specifies what a reader needs in order to evaluate the study. The GPP declaration layer informs the reader who conducted the work, who funded it, who controlled it and what other outputs exist from the same data. Both can be checked within a single afternoon, and the second is the shorter of the two.
GPP reporting at a glance
- Current GPP
- GPP 2022 (DeTora et al., Annals of Internal Medicine), covering manuscripts, meeting presentations, posters, abstracts and plain-language summaries5
- Trial reports
- CONSORT 2025: a 30-item checklist and a participant flow diagram29
- Systematic reviews
- PRISMA 2020: a 27-item checklist, an abstract checklist and revised flow diagrams30
- Most often omitted
- Recruitment dates, flow diagram, primary outcome and registration number8
- Reading time
- About 15 minutes, with 3 figures and 3 tables
Learning objectives
- The two layers of GPP reporting, and which items belong to which
- Selection of the appropriate reporting guideline for a given design, including the 13-item CARE checklist for case reports
- The CONSORT items most often omitted, with the item-level risk ratios from Gattrell and colleagues
- The seven GPP declarations for which no reporting guideline provides a prompt
- Why the abstract is a separate reporting object with its own checklist and its own failure modes
- What the evidence does and does not show about whether following a reporting guideline improves anything
Common misconceptions
- “GPP contains the reporting standard.” GPP does not contain a reporting standard. GPP requires use of the appropriate reporting guideline; CONSORT, PRISMA, STROBE and CARE are separate documents maintained by separate groups.
- “The checklist is a submission formality.” Each unmet item is likely to be raised by a reviewer as a criticism. Used as a drafting prompt rather than a submission artefact, the same checklist can avert a revision round.
- “The abstract is a summary of the paper.” For a trial report, the abstract is a reporting object in its own right, with its own CONSORT extension, and it is the only part of the report that most readers will see.
- “Following a reporting guideline will improve my paper’s reception.” The evidence that guideline endorsement improves reporting completeness is real but of limited quality. No study has shown that it improves acceptance or impact.
- “A congress abstract is too short to need the declarations.” It is the output most often managed to a lower standard, and GPP treats it as part of the same disclosure obligation as the paper.
The two layers of GPP reporting and the informal handling of the second
The first layer is the reporting guideline for the study design. Its purpose is to enable a reader to evaluate the research: how participants were allocated, what the primary outcome was, how many participants were lost to follow-up and what was pre-specified. GPP refers to these documents without containing them 5,9.
The second layer is the GPP declaration set: who qualifies as an author and who does not, who contributed and who funded each contribution, what role the sponsor played, what access the authors had to the data, what else has already been published from this dataset, and where the data will be available. No reporting guideline requests most of this information, and only part of it appears on a submission form.
The consequence is predictable. The first layer is typically documented in a completed checklist attached to the submission, because journals increasingly require one. The second layer is often assembled shortly before upload, from memory, by whichever team member holds the file, which explains why the end matter of otherwise careful papers so often states “editorial assistance was provided” and “data are available on reasonable request”. The disclosure topics most frequently omitted are catalogued on the GPP topics authors most often miss; this page is the checklist form of both layers.
Selection of the reporting guideline and its value
The guideline should be matched to the study design rather than to the journal. CONSORT 2010, from Schulz, Altman and Moher in Annals of Internal Medicine, covers parallel-group randomised trials, with extensions including one for abstracts from Hopewell and colleagues in PLoS Medicine 13,17. PRISMA, from Moher and colleagues in PLoS Medicine, covers systematic reviews and meta-analyses 15. STROBE, from von Elm and colleagues in BMJ, covers observational epidemiology 19. CARE, developed by Gagnier and colleagues, covers case reports: the CARE checklist has 13 items and was developed by 27 participants from 28 contacted, with 18 phase I participants attending the face-to-face consensus meeting, and Riley and colleagues published the explanation and elaboration document in the Journal of Clinical Epidemiology 6,10.
Claims that reporting guidelines improve reporting require caution. Turner and colleagues’ Cochrane review examined whether use of the CONSORT statement improves the completeness of randomised trial reporting; the review drew on 16,604 randomised trials reported in 53 publications, and concluded that journal endorsement of CONSORT is associated with more complete reporting, while noting that the evidence is of limited quality and largely observational 11. Hopewell and colleagues, in BMJ, used an interrupted time series to examine the effect of editors actively implementing the CONSORT abstract extension rather than merely endorsing it 12,17.
The evidence therefore shows an association with better reporting, which is stronger where editors actively enforce the guideline at submission, and no demonstrated effect on acceptance or impact. This supports use of the checklist as a drafting prompt, where the benefit plausibly lies, rather than as a compliance artefact generated after the fact. Guideline selection by design type is covered on reporting guidelines.
Two of these guidelines have since been updated. CONSORT 2025, from Hopewell and colleagues, followed a scoping review, a three-round Delphi survey with 317 participants and a two-day consensus meeting of 30 experts29. PRISMA 2020, from Page and colleagues, replaces the 2009 statement with a 27-item checklist30.
Layer 1: which reporting guideline for which design
| Design | Guideline | Scope | GPP declarations still needed? |
|---|---|---|---|
| Parallel-group randomised trial | CONSORT 202529 | 30 items plus a participant flow diagram; replaces CONSORT 20101329 | Yes: authorship, contributors, sponsor role, data access, prior disclosure, conflicts, data availability |
| Trial abstract (journal or congress) | CONSORT for abstracts17 | Separate checklist for the abstract | Yes, including writing support and authorship on congress abstracts |
| Systematic review or meta-analysis | PRISMA 202030 | 27 items, an abstract checklist and revised flow diagrams; replaces PRISMA 20091530 | Yes |
| Observational study | STROBE19 | Observational studies in epidemiology | Yes |
| Case report | CARE106 | 13 items | Yes |
No reporting guideline asks for the full GPP declaration layer, so the last column is the same for every design.5
What changed between CONSORT 2010 and CONSORT 2025
| Change | Detail |
|---|---|
| New items | 7 checklist items added |
| Revised items | 3 items revised |
| Deleted items | 1 item deleted |
| Integrated extensions | Items brought in from the Harms, Outcomes and Non-pharmacological Treatment extensions, and from TIDieR |
| New section | A section on open science |
| Result | 30-item checklist, a participant flow diagram and an expanded checklist with bullet points for each item |
As reported in the CONSORT 2025 statement.29
Most frequently omitted reporting items
Checklist items are not omitted at the same rate, and the pattern is informative. Gattrell and colleagues, in BMJ Open, compared CONSORT reporting in randomised trial reports with and without declared professional medical writing support, and reported which items the difference was concentrated in. The items most improved by writing support were recruitment and follow-up dates (risk ratio 2.04), the participant flow diagram (1.96), specification of the primary outcome (1.77) and trial registration details (1.64) 8.
This list indicates which items tend to be omitted under time pressure. All four are mechanical; none requires judgement, new analysis or a difficult discussion among authors. Recruitment dates, a flow diagram, a clearly named primary outcome and a registration number are items that are either remembered or omitted, which is precisely the profile of a task that benefits from a checklist and an independent second review.
The overall figures from the same study: among 233 randomised controlled trial reports, 39.1% (43 of 110) of those with declared writing support completely reported at least half the assessed CONSORT items, against 21.1% (26 of 123) without support 8. Adjusting for publication year, the odds of completely reporting at least half the items were 1.88 times higher with support, with a 95% confidence interval of 1.03 to 3.42 8. Because the design is cross-sectional and the lower bound of the interval approaches 1, this finding represents an association rather than a demonstrated effect of engaging a professional writer 8.
CONSORT items most improved where professional medical writing support was declared, as risk ratios. Source: Gattrell WT, Hopewell S, Young K, Farrow P, White R, Wager E, Winchester CC. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open.
The seven GPP declarations
These are the items GPP adds, in the order they appear in a manuscript’s end matter.
1. Authorship. Every author meets the ICMJE criteria; the contributorship statement reports who did what 1,9. Any individual who does not meet them is listed in the acknowledgements rather than retained as an author without disclosure.
2. Contributions and funding of contributions. Each non-author contributor is named, with their employer and the funder of their work: writer, statistician, agency, language editor or patient contributor. Written permission is obtained from each.
3. Role of the sponsor. This covers not only the funding source but also the sponsor’s role across study design, conduct, analysis and the decision to publish, and who held editorial control 5,9.
4. Author access to data. Access is stated at the level that accurately reflects the arrangement: final outputs only, analyses on request, or access to the analysis dataset.
5. Prior and related disclosure. This includes congress abstracts, posters, preprints with DOIs and the primary report if the manuscript is a secondary analysis, together with the cross-reference drafted into the abstract and methods. The evidence on detection that underlies this item is presented on how duplicate publication is identified.
6. Conflicts of interest. Conflicts are itemised per author rather than asserted collectively.
7. Data availability. The statement specifies a route, a custodian, a date from which the data are available, and the conditions. “On reasonable request” names none of these.
The seven items amount to approximately 150 words. The full worksheet is provided at the end of this page.
The GPP reporting checklist, both layers
| Layer | Item | Where it goes | Prompted by a submission form? |
|---|---|---|---|
| 1 — guideline | Reporting guideline for the design: CONSORT, PRISMA, STROBE, CARE (13 items), or the relevant extension | Throughout; checklist attached | Increasingly yes |
| 1 — guideline | Abstract checklist for trial reports (CONSORT for abstracts) | Abstract | Rarely |
| 2 — declaration | Authorship against the ICMJE criteria, with contributorship statement | Title page and end matter | Yes |
| 2 — declaration | Non-author contributors: name, employer, role, funder, written permission | Acknowledgements | Partly |
| 2 — declaration | Role of the sponsor across design, conduct, analysis, decision to publish; who held editorial control | End matter | Partly — often free text |
| 2 — declaration | Author access to data, at the level that is true | End matter | No |
| 2 — declaration | Prior and related disclosure: abstracts, posters, preprints, primary report | Title-page footnote, abstract, cover letter | Sometimes |
| 2 — declaration | Conflicts of interest, itemised per author | End matter | Yes |
| 2 — declaration | Data availability: route, custodian, date, conditions | End matter | Often, as free text |
Compiled from GPP3 (Battisti et al., Annals of Internal Medicine), GPP 2022 (DeTora et al., Annals of Internal Medicine), the ICMJE Recommendations, and the named reporting guidelines. The final column is our observation of common submission systems, not a statement from any of those documents.
Weak data-availability statement
“Data are available from the corresponding author on reasonable request.”
No route, no custodian, no date and no condition. A reader cannot tell whether a request would ever succeed.
Stronger data-availability statement
“De-identified participant data and the statistical analysis plan will be available from [repository] 12 months after publication, to researchers with an approved proposal, on signature of a data-sharing agreement with [sponsor].”
Illustrative wording. It names the route, the custodian, the start date and the condition, as the declaration table above asks.
The abstract as a separate reporting object
For most readers the abstract is the paper, and for trial reports it has its own checklist — the CONSORT extension for journal and conference abstracts, from Hopewell and colleagues in PLoS Medicine 17. Mills and colleagues, in F1000Research, looked specifically at the reporting quality of randomised trial abstracts in high-impact general medical journals in relation to professional writing support 7.
Two failure modes predominate, and both are identifiable in a single reading. The first is reporting a direction without a number: “significantly improved” with no effect size, no interval and no denominator. The second is a conclusion that the results do not support, such as a secondary endpoint promoted to the headline, or an efficacy claim from a trial that was not powered for it.
The remedy is a brief, systematic check: an abstract for a trial report should name the design, the setting, the participants and their number, the primary outcome with its timing, the effect size with a confidence interval, the harms, the registration number, and a conclusion that does not exceed the primary result. This check can be applied in five minutes to a completed draft.
Five-minute abstract check for a trial report
- Design and setting are named.
- Participants are described, with the number randomised.
- The primary outcome is stated with its timing.
- The effect size is given with a confidence interval, not a p value alone.
- Harms are reported as rates in both arms.
- The registration number is present.
- The conclusion does not go beyond the primary result.
Alternative reporting of identical results
The following example presents a trial abstract’s results and conclusion section in the form typically submitted and in a revised form that answers the questions a reviewer would otherwise raise. The revised version is approximately forty words longer.
A trial abstract’s results and conclusion, before and after
Direction only
Results: Treatment with tenovir significantly improved symptom scores compared with placebo (p<0.001). Improvements were also seen in secondary endpoints. Tenovir was generally well tolerated, with no unexpected safety findings. Conclusions: Tenovir is an effective and well-tolerated treatment for moderate-to-severe disease and represents an important new option for patients.
No effect size. “Significantly improved” with a p value conveys nothing about the magnitude of the effect.
No denominator and no follow-up account. The numbers randomised and the numbers who completed are not stated.
“Secondary endpoints” unnumbered and unnamed, which raises the possibility of selective reporting.
“Generally well tolerated” reports no harms data at all — a characterisation in place of a number.
The conclusion exceeds the result and adds a positioning claim (“important new option”) the trial did not test.
No registration number, which is one of the items most often dropped under time pressure.
Reportable
Results: Of 412 participants randomised at 18 centres between March 2022 and January 2023, 389 (94.4%) completed the 24-week primary assessment. Mean symptom score improved by 2.4 points more with tenovir than placebo (95% CI 1.1 to 3.7; p<0.001), against a pre-specified minimal clinically important difference of 2.0 points. Of 6 secondary endpoints, 2 reached the pre-specified threshold. Adverse events occurred in 61.2% of the tenovir group and 54.8% of placebo; serious adverse events in 4.9% and 4.3%; 11 participants discontinued for adverse events in the tenovir group versus 4 on placebo. Conclusions: In adults with moderate-to-severe disease, tenovir improved symptom scores over 24 weeks by a margin exceeding the pre-specified clinically important difference, with a higher rate of discontinuation for adverse events than placebo. Longer-term effects are unknown. ISRCTN00000000.
Effect size with a confidence interval, and a pre-specified threshold to judge it against.
Randomised and completed numbers, with the recruitment window — the CONSORT item with the highest risk ratio in Gattrell and colleagues’ data.
Secondary endpoints counted, so the reader can see how many were tested and how many succeeded.
Harms reported as rates in both arms, including discontinuations, rather than characterised.
The conclusion is bounded by what was measured, with the unknown stated rather than filled in.
Registration number present, tying the abstract to the registered protocol.
The additional forty words remove six separate grounds for a reviewer query, and each addition corresponds to a CONSORT item. The items at issue (dates, flow, primary outcome and registration) are the four that Gattrell and colleagues found most improved where writing support was declared, with risk ratios of 2.04, 1.96, 1.77 and 1.64. They are mechanical, which is why a checklist used during drafting identifies them whereas a checklist completed at submission does not.
Outputs other than journal articles
GPP’s reporting expectations do not stop at the journal article, and the 2022 update from DeTora and colleagues in Annals of Internal Medicine is explicit about the wider set of outputs 5. Three warrant separate attention.
Congress abstracts and posters. Congress abstracts are the outputs in which the declaration layer is most commonly omitted: no writer is declared, the author list differs from that of the eventual paper, and the conclusion exceeds what the full analysis will support. A congress abstract is prior disclosure of the data and should carry the same authorship logic and the same acknowledgement of writing support as the paper.
Plain-language summaries. These require the most demanding editorial judgement, because simplification can alter a claim. The test is whether the summary’s conclusion would be defensible if a reviewer read it alongside the primary result. Woloshin and colleagues, in Annals of Internal Medicine, examined press releases from academic medical centres and found the same failure mode in the lay-facing layer: claims outrunning the underlying evidence.
Registry results postings. These are a reporting obligation in their own right, with their own deadlines, and constitute the only public record of a completed study if no paper is written.
What GPP 2022 covers beyond the journal article
The 2022 update applies to peer-reviewed or peer-oriented biomedical publications, including manuscripts, meeting presentations, posters and abstracts, and to enhanced content such as plain-language summaries. Its supplemental materials cover steering committees, publication plans, publication working groups, authorship decisions and documentation, with new material on alliances and working with patients.5
Scope and limits of the reporting evidence
Three limitations should be acknowledged, because overclaiming in this area is common and readily detected.
First, completeness of reporting is not quality of research. A fully CONSORT-compliant report of an underpowered trial is a well-reported underpowered trial. The checklist makes a study legible, which is a precondition for judging it and not a substitute.
Second, the evidence that guidelines improve reporting is observational. Turner and colleagues’ Cochrane review, drawing on 16,604 trials across 53 publications, found an association with journal endorsement while describing the evidence as limited in quality 11. No study has randomised journals to endorse CONSORT.
Third, the professional-writing-support findings are associations and should be quoted with their caveats. Gattrell and colleagues also found that peer reviewers judged the written English acceptable in 81.1% of articles with writing support against 47.9% without; this is a large difference, but it derives from a cross-sectional comparison in which the papers with support differ from those without in ways beyond the support itself 8. The finding is a reasonable argument for assistance with reporting completeness and language. It is not evidence about acceptance, impact or the trustworthiness of the findings, and citing it in that way is likely to be challenged.
Takeaway
Key points
Key points
A GPP-compliant publication satisfies two checklists. The first is the reporting guideline for the design (CONSORT, PRISMA, STROBE or CARE’s 13 items), which GPP requires but does not contain, and whose benefit the evidence locates in reporting completeness rather than in acceptance. The second is a seven-item declaration layer that no reporting guideline prompts: authorship, contributions with their funders, sponsor role, author data access, prior disclosure, itemised conflicts, and a data-availability statement that names a route and a date. The items most often omitted are mechanical (dates, flow diagram, primary outcome and registration), which is why the checklist belongs in drafting rather than at submission.
Application to your study
Application to your study
- The reporting guideline should be identified before drafting and consulted alongside the manuscript. The appropriate guideline is CONSORT for parallel-group trials, PRISMA for reviews, STROBE for observational studies, CARE’s 13 items for case reports, or the relevant extension.
- The four mechanical items should be checked first. These are recruitment and follow-up dates, the participant flow diagram, a single named primary outcome with its timing, and the registration number; they are the items most often omitted.
- The abstract should be checked separately against the abstract checklist. The abstract should report design, setting, participants and number, primary outcome with timing, effect size with interval, harms, registration and a bounded conclusion.
- Every qualitative characterisation of harms should be replaced with a rate in both arms. A description such as “well tolerated” does not constitute a result.
- The seven declarations should be written as a single block rather than as separate additions. These comprise authorship, contributions with funders, sponsor role, data access, prior disclosure, itemised conflicts and data availability.
- The statement “available on reasonable request” should be rewritten to specify a route, a custodian, a start date and a condition, or should state transparently that data will not be shared.
- The same declaration layer should be applied to the congress abstract. The same authorship logic, writing-support acknowledgement and conclusion discipline apply.
- The conclusion should be assessed against the primary outcome alone. If the conclusion depends on a secondary endpoint or a positioning claim, it should be reduced accordingly.
Frequently asked questions
No; this is the most common misreading of GPP. GPP requires that publications follow the appropriate reporting guideline for the study design, but the guidelines themselves are separate documents maintained by separate groups: CONSORT 2010 from Schulz, Altman and Moher for parallel-group randomised trials, PRISMA from Moher and colleagues for systematic reviews, STROBE from von Elm and colleagues for observational studies, and CARE from Gagnier and colleagues for case reports. What GPP adds is a second layer that the reporting guidelines do not cover: authorship, contributions and their funders, the sponsor’s role, author data access, prior disclosure, conflicts and data availability.
The mechanical items. Gattrell and colleagues, in BMJ Open, found that the CONSORT items most improved where professional writing support was declared were recruitment and follow-up dates (risk ratio 2.04), the participant flow diagram (1.96), specification of the primary outcome (1.77) and trial registration details (1.64). None of these requires judgement or new analysis; they are either remembered or omitted. This is precisely the category of task that a checklist used during drafting identifies and a checklist completed at submission does not.
The evidence supports better reporting completeness and nothing beyond that. Turner and colleagues’ Cochrane review, drawing on 16,604 randomised trials reported in 53 publications, found journal endorsement of CONSORT associated with more complete reporting while describing the evidence as limited in quality and largely observational. Hopewell and colleagues, in BMJ, examined what happened when editors actively implemented the abstract extension rather than merely endorsing it. No study shows that following CONSORT improves acceptance, citation or impact, and completeness of reporting is not the same thing as quality of research.
The CARE checklist has 13 items. CARE was developed by Gagnier and colleagues through a consensus process involving 27 participants out of 28 contacted, with 18 phase I participants attending the face-to-face consensus meeting, and Riley and colleagues published the explanation and elaboration document in the Journal of Clinical Epidemiology. Thirteen items can readily be checked directly against a draft, which is the main practical argument for using the checklist as a drafting prompt. Case reports are also the design in which patient consent and de-identification require the most attention, and CARE addresses both.
The statement names no route, no custodian, no date and no conditions, so a reader cannot determine whether the data are obtainable or who decides. A usable statement specifies where a request should be sent, who holds the data, from when they are available, and what conditions apply, for example a data-sharing agreement or an approved analysis plan. A statement that data will not be shared is also acceptable where that is the position; what is not acceptable is a form of words that implies availability without providing it. The ICMJE requires trial reports to contain a data sharing statement, and “reasonable request” technically satisfies that requirement while conveying no usable information.
Yes; congress abstracts are the outputs in which the declaration layer is most often omitted. A congress abstract is prior disclosure of the data, and GPP 2022, from DeTora and colleagues in Annals of Internal Medicine, treats non-journal outputs as part of the same obligation. In practice, this requires the same authorship logic, the same acknowledgement of writing support by named individual and funder, and the same discipline about not drawing a conclusion that the full analysis will not support. It also requires the abstract to be declared to the journal when the paper is submitted, since publisher similarity-checking software will detect it in any case.
The study can be cited reliably provided that its limitations are stated. Gattrell and colleagues, in BMJ Open, found 39.1% of 110 trial reports with declared writing support completely reported at least half the assessed CONSORT items against 21.1% of 123 without, an adjusted odds ratio of 1.88 with a 95% confidence interval of 1.03 to 3.42, and that reviewers judged the written English acceptable in 81.1% versus 47.9%. Both are cross-sectional comparisons, the CONSORT interval approaches 1, and papers with support differ from those without in ways beyond the support. It supports a claim about reporting completeness and language, not about acceptance or impact.
Only what the primary outcome supports, with any unknowns stated. The two dominant failure modes in trial abstracts are reporting a direction without a number (“significantly improved” with no effect size, interval or denominator) and a conclusion that relies on a secondary endpoint or adds a positioning claim that the trial did not test. A conclusion can be tested by covering the secondary results and rereading it: if it no longer stands, it should be reduced. The registration number should be added at the same stage, since it is one of the items most frequently omitted.
References
- International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. ICMJE. 2026. read 9 October 2026. icmje.org
- International Committee of Medical Journal Editors. The New ICMJE Recommendations (August 2013). ICMJE. 2013. read 9 October 2026. icmje.org
- Committee on Publication Ethics. Core Practices. COPE. read 9 October 2026. equator-network.org
- International Society for Medical Publication Professionals. GPP 2022: Good Publication Practice guidelines for company-sponsored biomedical research published in Annals of Internal Medicine (press release). ISMPP. 2022. read 9 October 2026. ismpp.org
- DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022;175(9):1298-1304. doi:10.7326/M22-1460 read 9 October 2026. doi.org/10.7326/M22-1460
- Riley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P, et al. CARE guidelines for case reports: explanation and elaboration document. Journal of Clinical Epidemiology. 2017;89:218-235. read 9 October 2026. community.the-hospitalist.org
- Mills I, Sheard C, Hays M, Douglas K, Winchester CC, Gattrell WT. Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals. F1000Research. 2017;6:1489. doi:10.12688/f1000research.12268.2 read 9 October 2026. doi.org/10.12688/f1000research.12268.2
- Gattrell WT, Hopewell S, Young K, Farrow P, White R, Wager E, Winchester CC. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open. 2016;6(2):e010329. doi:10.1136/bmjopen-2015-010329 read 9 October 2026. doi.org/10.1136/bmjopen-2015-010329
- Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, Citrome L, Gurr JA, Mooney LA, Moore BJ, Pena T, Sanes-Miller CH, Veitch K, Woolley KL, Yarker YE. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. doi:10.7326/M15-0288 read 9 October 2026. doi.org/10.7326/M15-0288
- Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Journal of Medical Case Reports. 2013;7(1):223. doi:10.1186/1752-1947-7-223 read 9 October 2026. doi.org/10.1186/1752-1947-7-223
- Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Systematic Reviews. 2012;1:60. read 9 October 2026. care-statement.org
- Hopewell S, Ravaud P, Baron G, Boutron I. Effect of editors' implementation of CONSORT guidelines on the reporting of abstracts in high impact medical journals: interrupted time series analysis. BMJ. 2012;344:e4178. read 9 October 2026. care-statement.org
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine. 2010;152:726-732. read 9 October 2026. care-statement.org
- Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, Field EA, Gurr JA, Marx M-E, Patel M, Sanes-Miller C, Yarker YE. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ. 2009;339:b4330. doi:10.1136/bmj.b4330 read 9 October 2026. doi.org/10.1136/bmj.b4330
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009;6:e1000097. read 9 October 2026. care-statement.org
- Gotzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Medicine. 2009;6(2):e1000023. read 9 October 2026. archive.emwa.org
- Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF; CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Medicine. 2008;5:e20. read 9 October 2026. care-statement.org
- Norris R, Bowman A, Fagan JM, Gallagher ER, Geraci AB, Gertel A, et al. International Society for Medical Publication Professionals (ISMPP) position statement. Current Medical Research and Opinion. 2007;23:1837-1840. read 9 October 2026. archive.emwa.org
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-808. read 9 October 2026. care-statement.org
- Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. Current Medical Research and Opinion. 2005;21:317-321. read 9 October 2026. archive.emwa.org
- von Elm E, Poglia G, Walder B, Tramer MR. Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA. 2004;291(8):974-980. doi:10.1001/jama.291.8.974 read 9 October 2026. doi.org/10.1001/jama.291.8.974
- Steinbrook R. Public registration of clinical trials. New England Journal of Medicine. 2004;351:315-317. doi:10.1056/NEJMp048191 read 9 October 2026. doi.org/10.1056/NEJMp048191
- Hamilton CW, Royer MG; AMWA 2002 Task Force on the Contributions of Medical Writers to Scientific Publications. AMWA position statement on the contributions of medical writers to scientific publications. AMWA Journal. 2003;18:13-16. read 9 October 2026. archive.emwa.org
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Current Medical Research and Opinion. 2003;19(3):149-154. doi:10.1185/030079903125001767 read 9 October 2026. doi.org/10.1185/030079903125001767
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies: why we need another set of guidelines. Current Medical Research and Opinion. 2003;19(3):147-148. read 9 October 2026. ismpp.org
- Antes G, Chalmers I. Under-reporting of clinical trials is unethical. Lancet. 2003;361:978-979. read 9 October 2026. ismpp.org
- Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research papers. BMJ. 1997;315:640-645. read 9 October 2026. ismpp.org
- Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-872. read 9 October 2026. ismpp.org
- Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123. read 13 November 2026. View on The BMJ
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. read 13 November 2026. View on The BMJ
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Reporting and Declaration Requirements Under GPP: A Working Checklist. Pubrica. https://pubrica.com/academy/concepts-definitions/reporting-standards-of-gpp/
Pubrica Academy. “Reporting and Declaration Requirements Under GPP: A Working Checklist.” Pubrica, 9 Oct. 2026, pubrica.com/academy/concepts-definitions/reporting-standards-of-gpp/.
Pubrica Academy (2026) Reporting and Declaration Requirements Under GPP: A Working Checklist. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/reporting-standards-of-gpp/ (Accessed: 15 October 2026).
Pubrica Academy. “Reporting and Declaration Requirements Under GPP: A Working Checklist.” Pubrica. October 9, 2026. https://pubrica.com/academy/concepts-definitions/reporting-standards-of-gpp/
Pubrica Academy, ‘Reporting and Declaration Requirements Under GPP: A Working Checklist’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/concepts-definitions/reporting-standards-of-gpp/> accessed 15 October 2026.
Pubrica Academy. Reporting and Declaration Requirements Under GPP: A Working Checklist. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/reporting-standards-of-gpp/
Pubrica Academy, “Reporting and Declaration Requirements Under GPP: A Working Checklist,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/reporting-standards-of-gpp/
@misc{reporting_standards_of_gpp_2026,
author = {{Pubrica Academy}},
title = {Reporting and Declaration Requirements Under GPP: A Working Checklist},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/reporting-standards-of-gpp/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Two-layer GPP reporting checklist
The first layer is the reporting guideline for the study design; the second is the GPP declaration set, which no guideline prompts. Both should be completed before submission, and the first should be applied during drafting, where it provides the greatest benefit.
GPP REPORTING CHECKLIST - TWO LAYERS
Manuscript: ______________________ Design: ______________________
LAYER 1 - REPORTING GUIDELINE
Guideline for this design: ______________________ (version: ________)
[ ] CONSORT 2010 - parallel-group randomised trial
[ ] CONSORT extension for abstracts - any trial report
[ ] PRISMA - systematic review / meta-analysis
[ ] STROBE - observational study
[ ] CARE (13 items) - case report
[ ] Other extension: ______________________
[ ] Full checklist completed line by line against the draft, not from memory
The four items that slip most (check these first):
[ ] Recruitment and follow-up dates stated
[ ] Participant flow diagram present and numbers reconcile
[ ] ONE named primary outcome, with its timing
[ ] Registration number present in the manuscript AND the abstract
ABSTRACT CHECK (run separately; most readers see only this)
[ ] Design named
[ ] Setting and number of centres
[ ] Participants randomised / included, and number completing
[ ] Primary outcome with timing
[ ] Effect size WITH confidence interval, not a p value alone
[ ] Comparator stated
[ ] Harms as rates in both arms, including discontinuations
[ ] Registration number
[ ] Conclusion supported by the primary outcome alone
[ ] No positioning or market language
LAYER 2 - GPP DECLARATIONS (seven items, about 150 words)
1. AUTHORSHIP
[ ] Every author meets the ICMJE criteria; grid on file
[ ] Contributorship statement reports who did what
[ ] Anyone not meeting the criteria moved to acknowledgements
2. CONTRIBUTIONS AND THEIR FUNDERS (name, employer, role, funder, permission)
writer ........ ____________________________________________ perm [ ]
statistician .. ____________________________________________ perm [ ]
agency ........ ____________________________________________ perm [ ]
other ......... ____________________________________________ perm [ ]
3. ROLE OF THE SPONSOR
[ ] design [ ] conduct [ ] analysis [ ] decision to publish
Editorial control held by: ______________________
4. AUTHOR ACCESS TO DATA (state the level that is true)
[ ] final outputs only [ ] analyses on request [ ] analysis dataset
5. PRIOR AND RELATED DISCLOSURE
Congress abstracts / posters: ______________________________________
Preprint + DOI: ______________________________________
Primary report (if this is secondary): ______________________________
[ ] Declared to the editor; cross-reference in title-page footnote and abstract
6. CONFLICTS OF INTEREST
[ ] Itemised per author, not asserted collectively
7. DATA AVAILABILITY
Route: ______________ Custodian: ______________
From: __________ Conditions: ______________________
[ ] Or: an explicit statement that data will not be shared, and why
NON-JOURNAL OUTPUTS FROM THE SAME DATA
[ ] Congress abstract carries the same authorship logic and writing-support
acknowledgement
[ ] Plain-language summary conclusion matches the primary result
[ ] Registry results posting completed / scheduled: __________ Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica applies the reporting guideline to a manuscript at the draft stage, when mechanical omissions can be identified, and prepares the abstract as a separate reporting object rather than a shortened introduction. Pubrica drafts the seven GPP declarations as a single block and identifies any data-availability or sponsor-role statement that conveys less than it appears to.